Overall, our study demonstrates that GSH can improve the engraftment efficiency of ADSCs in liver fibrosis by inhibiting the TGFβ1/SMAD3/NOX4 signaling pathway (Figure 7). Here, NOX4 is linked to Hepatic fibrosis.